TrovaGene is pioneering a new field of cancer diagnostics by using a urine-based liquid biopsy platform. The company has a number of CLIA available tests on the market and expects to spend the next few months collecting data and seeking reimbursement from payers. So far the rollout looks to be going very well, but it is still early in the launch. Nevertheless, despite being early I see significant potential for the company's platform I believe the shares are undervalued as of today.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.